Drugs / Olmesartan medoxomil
Olmesartan medoxomil
also known as
olmesartan · Olmetec · ATB-1011 · Benicar · Benicar (olmesartan medoxomil) · CS-866 · OLM
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | BENICAR | — | 2010-02-04 | fda.gov ↗ |
| Approved | US (FDA) | BENICAR | — | 2002-04-25 | fda.gov ↗ |
Trials 55
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07590466 | May → Jul 2026 overdue | hypertensive disorder, type 2 diabetes mellitus | Autotelicbio | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT02058472 | Dec 2013 → May 2014 | — | Dong-A Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01415466 | Aug → Sep 2011 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT02962258 | May → Jun 2011 | — | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1 | NCT01019590 | Nov 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT01020214 | Nov 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648219 | Dec 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649623 | Dec 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00151814 | Sep 2005 → Feb 2008 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00914524 | Jan 2005 → Apr 2006 | diabetic kidney disease, glomerulonephritis | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT00151775 | May 2005 → Sep 2008 | hypertensive disorder | Daiichi Sankyo | Completed | Met primary |
| Phase 323 trials · 6 met primary · 2 missed | ||||||
| Phase 3 | NCT01838850 | Apr 2013 → Aug 2014 | essential hypertension | Daiichi Sankyo | Completed | Met primary |
| Phase 3 | NCT00923091 | Jun 2009 → Jan 2011 | essential hypertension | Daiichi Sankyo | Completed | Met primary |
| Phase 3 | NCT00891267 | Oct 2008 → Apr 2011 | hypertensive disorder, metabolic syndrome X | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT00676845 | Aug 2008 → May 2011 | hypertensive disorder, metabolic syndrome X | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT00679484 | Jun 2008 → Nov 2009 | symptomatic heart failure | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00649389 | May 2008 → Apr 2009 | hypertensive disorder | Daiichi Sankyo | Completed | Met primary |
| Phase 3 | NCT00527514 | Sep 2007 → Apr 2008 | hypertensive disorder | Daiichi Sankyo | Completed | Met primary |
| Phase 3 | NCT00430508 | Feb 2007 → Mar 2008 | essential hypertension | Daiichi Sankyo | Completed | Met primary |
| Phase 3 | NCT00430950 | Feb 2007 → May 2008 | essential hypertension | Daiichi Sankyo | Completed | Missed primary |
| Phase 3 | NCT00185133 | May 2005 → Jan 2007 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00220233 | Apr 2005 → Aug 2007 | essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT00185159 | Oct 2004 → Jul 2009 | cardiovascular disorder, kidney disorder, type 2 diabetes mellitus | Sankyo Pharma Gmbh | Completed | Met primary |
| Phase 3 | NCT00856271 | Aug 2004 → Feb 2005 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00151827 | Aug 2003 → Jul 2005 | essential hypertension, impaired renal function disease | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT00751829 | Jul 2003 → Oct 2004 | — | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT00751751 | Jun 2003 → Apr 2005 | essential hypertension | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT00362960 | May 2003 → Sep 2004 | diabetic kidney disease, proteinuria, type 2 diabetes mellitus | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT00141453 | Apr 2003 → Aug 2008 | diabetic kidney disease, proteinuria, type 2 diabetes mellitus | Daiichi Sankyo | Completed | Missed primary |
| Phase 3 | NCT00857285 | May 2002 → Aug 2003 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00185172 | Jan 2002 → Jun 2005 | essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT00185185 | Nov 2001 → Feb 2006 | atherosclerotic cardiovascular disease, essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT00382213 | Jun 2000 → Dec 2004 | atherosclerosis | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02483936 | ? → Jun 2025 | essential hypertension | EMS | Withdrawn | No outcome recorded |
| Phase 420 trials · 7 met primary | ||||||
| Phase 4 | NCT04061824 | May 2016 → Dec 2018 | hyperlipidemia, hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02495324 | Jun 2015 → May 2017 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | Met primary |
| Phase 4 | NCT02377661 | Mar 2015 → May 2017 | hypertensive disorder | Wilhelminenspital Vienna | Completed | Met primary |
| Phase 4 | NCT02360956 | Dec 2014 → Jun 2016 | coronary atherosclerosis | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01611077 | Jan → Dec 2012 | essential hypertension | Institute for Pharmacology and Preventive Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01132768 | May 2010 → Jun 2011 | carotid artery disorder, essential hypertension | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00949884 | Aug 2009 → Jan 2010 | hypertensive disorder | Daiichi Sankyo | Completed | Met primary |
| Phase 4 | NCT01684748 | Feb 2009 → Aug 2011 | hypertensive disorder, obesity disorder | Virginia Polytechnic Institute and State University | Completed | No outcome recorded |
| Phase 4 | NCT00791258 | Nov 2008 → Aug 2009 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00654745 | May 2008 → Apr 2009 | essential hypertension, type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00412932 | Dec 2006 → Apr 2008 | hypertensive disorder | Daiichi Sankyo | Completed | Met primary |
| Phase 4 | NCT00430638 | Dec 2006 → Oct 2007 | hypertensive disorder | Daiichi Sankyo | Completed | Met primary |
| Phase 4 | NCT00403481 | Nov 2006 → Nov 2007 | hypertensive disorder | Daiichi Sankyo | Completed | Met primary |
| Phase 4 | NCT00890591 | Aug 2006 → Jun 2007 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00311155 | Mar 2006 → Apr 2008 | essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 4 | NCT00185120 | Sep 2005 → Sep 2006 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00185055 | Nov 2004 → Feb 2005 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00185068 | Mar → Oct 2004 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00185094 | Feb 2004 → Jul 2005 | hypertensive disorder, metabolic syndrome X | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00772499 | Nov 2002 → Jul 2005 | essential hypertension | Daiichi Sankyo | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT07679828 | Jul 2026 → Dec 2029 expected | hyperlipidemia, hypertensive disorder, type 2 diabetes mellitus | China Medical University, China | Recruiting | No outcome recorded |
| Comparator or background therapy23 trials | ||||||
| Phase 1 | NCT01493856 Comparator | Jan → Feb 2012 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 2 | NCT05033535 Comparator | Jul 2020 → Dec 2021 | essential hypertension | Shenzhen People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02609490 Comparator | Sep 2015 → Feb 2017 | essential hypertension | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 3 | NCT02407210 Comparator | Jan → Oct 2015 | essential hypertension | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01309828 Comparator | Mar 2011 → Oct 2012 | — | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01033071 Comparator | Jan → Oct 2010 | essential hypertension | Takeda | Completed | Met primary |
| Phase 3 | NCT00996281 Comparator | Oct 2009 → Nov 2011 | essential hypertension | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00902538 Background | Apr 2009 → Sep 2010 | essential hypertension | Daiichi Sankyo | Completed | Mixed |
| Phase 3 | NCT00846365 Comparator | Mar 2009 → Jun 2010 | essential hypertension | Takeda | Completed | Met primary |
| Phase 3 | NCT00523744 Background | Jul → Dec 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00441350 Comparator | Jul 2007 → May 2008 | hypertensive disorder | Menarini Group | Completed | Met primary |
| Phase 3 | NCT00417222 Comparator | Nov 2006 → Mar 2013 | heart failure | Tohoku University | Completed | No outcome recorded |
| Phase 3 | NCT00872586 Comparator | Aug 2006 → Jul 2007 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00220220 Background | Apr 2005 → Apr 2007 | essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 4 | NCT07547878 Comparator | Apr 2026 → Mar 2029 expected | chronic kidney disease, type 2 diabetes mellitus | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT01180205 Comparator | Aug 2010 → Oct 2011 | hypertensive disorder | Johannes Gutenberg University Mainz | Unknown | No outcome recorded |
| Phase 4 | NCT01907373 Comparator | Aug → Sep 2009 | — | Central South University | Completed | No outcome recorded |
| Phase 4 | NCT00454662 Comparator | Apr 2007 → Sep 2011 | diabetes mellitus, hypertensive disorder | COLM Study Research Organization | Completed | No outcome recorded |
| Phase 4 | NCT00607035 Background | May 2006 → Apr 2008 | hypertensive disorder | Jichi Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00134160 Comparator | Aug 2005 → May 2010 | hypertensive disorder | OSCAR Study | Completed | No outcome recorded |
| Phase 4 | NCT00858702 Background | Feb → Jul 2005 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| — | NCT03015311 Background | Jan 2017 → Dec 2020 | essential hypertension | Chinese Academy of Medical Sciences, Fuwai Hospital | Unknown | No outcome recorded |
| — | NCT02848170 Comparator | Aug 2016 → Apr 2017 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 20
| Date | Issuer | Release |
|---|---|---|
| 2023-02-28 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Olmesartan Medoxomil and Hydrochlorothiazide Tablets zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg (USRLD: Benicar HCT ® Tablets). |
| 2021-02-18 | Daewoong Pharmaceutical Co. LTD. | Results Daewoong Pharmaceutical’s Olostar confirmed better effect than co-administration of individual drugs daewoong.co.kr ↗
The results showed that the Olostar group showed a higher level of adherence and improved both systolic and diastolic blood pressure. |
| 2020-11-30 | Daewoong Pharmaceutical Co. LTD. | Results Daewoong Pharmaceutical’s Olostar proved its excellent blood pressure reduction effects… Published in an SCI-grade journal daewoong.co.kr ↗
The results of the research indicated a meaningful decrease in both systolic and diastolic blood pressure on group with Olostar relative to the other group that was administered a combination of other ARBs and atorvastatin. |
| 2019-03-04 | Daewoong Pharmaceutical Co. LTD. | Regulatory Daewoong Pharmaceutical has completed the lineup of hypertension medications with the approval of ‘Olomax.’ daewoong.co.kr ↗
Daewoong Pharmaceutical (CEO Sengho Jeon) announced last 27th that KFDA has approved ‘Olomax,’ the compound of Amlodipine added to ‘Olostar,’ the existing compound of Olmesartan and Rosuvastatin. |
| 2017-04-28 | Lupin Limited | Regulatory Lupin receives FDA approval for generic Benicar® Tablets lupin.com ↗ |
| 2017-02-15 | Daiichi Sankyo | Regulatory Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha daiichisankyo.com ↗
Today, Daiichi Sankyo Espha obtained approval for manufacturing and marketing for multiple AG products, including the following products: |
| 2016-12-25 | Lupin Limited | Regulatory Lupin Receives Tentative Approval for Generic Benicar® Tablets lupin.com ↗ |
| 2016-03-17 | Daewoong Pharmaceutical Co. LTD. | Results Daewoong Pharmaceuticals - Daiichi-Sankyo Korea Expect sales of 30 billion won this year with Sevikar HCT daewoong.co.kr ↗
Whereas a double combination drug of Amlodipine and Olmesartan Medoxomil were not effective, Sevikar HCT displayed significant reduction in both systolic and diastolic pressure. |
| 2014-02-10 | Daewoong Pharmaceutical Co. LTD. | Regulatory Daewoong Pharmaceutical received domestic approval for its OLOSTAR, the new complex combining the Olmesatan and rosuvastatin for the first time worldwide daewoong.co.kr ↗
Daewoong Pharmaceutical Co.,Ltd(President: Lee Jong-wook) received the approval from the Ministry of Food and Drug Safety(MFDS) for its OLOSTAR, a new anti-hypertensive drug which was developed with its proprietary technology. |
| 2011-07-04 | Daewoong Pharmaceutical Co. LTD. | Results Sevikar, antihypertensive agent, proved 24 hours long effect daewoong.co.kr ↗
As a result, it was found that Sevikar reached target BP for 24 hours (70.9%), and had an excellent BP reduction in systolic pressure compared with placebo at 21.4mmHg. |
| 2010-12-21 | Daiichi Sankyo | Regulatory Daiichi Sankyo Announces First European Approval for Sevikar HCT(R), a New Three-in-one Combination Product for the Treatment of High Blood Pressure* daiichisankyo.com ↗
Daiichi Sankyo Europe announced today that Sevikar HCT® is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP). |
| 2010-07-27 | Daiichi Sankyo | Regulatory FDA APPROVES TRIBENZOR™, A NEW THREE-IN-ONE COMBINATION PRODUCT FOR THE TREATMENT OF HIGH BLOOD PRESSURE daiichisankyo.com ↗
FDA APPROVES TRIBENZOR™, A NEW THREE-IN-ONE COMBINATION PRODUCT FOR THE TREATMENT OF HIGH BLOOD PRESSURE |
| 2010-02-15 | Daiichi Sankyo | Regulatory FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16(1) daiichisankyo.com ↗
Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. |
| 2010-01-20 | Daiichi Sankyo | Regulatory Daiichi Sankyo Receives Approval to Manufacture and Market Rezaltas(R) Combination Tablets to Treat Hypertension daiichisankyo.com ↗
Daiichi Sankyo Company, Limited (hereafter; Daiichi Sankyo) today announced that it has received approval in Japan to manufacture and market Rezaltas® combination tablets LD and HD for the treatment of hypertension. |
| 2008-06-18 | Daiichi Sankyo | Results New Study Shows Benicar(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering daiichisankyo.com ↗
In the VIOS trial, olmesartan medoxomil, through early blockade of angiotensin II, improved the structure abnormalities of resistance arteries in patients with hypertension as measured by arterial wall to lumen ratio (W/L), returning arterial architecture to normal levels after one year of treatment. |
| 2007-10-01 | Daiichi Sankyo | Regulatory DAIICHI SANKYO EUROPE is applying for approval of its new combination product of Olmesartan and Amlodipin daiichisankyo.com ↗
DAIICHI SANKYO EUROPE GmbH has applied in 28 European countries for approval of a new antihypertensive medication. |
| 2007-09-28 | Daiichi Sankyo | Regulatory AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure daiichisankyo.com ↗
Daiichi Sankyo, Inc. announced today that the United States Food and Drug Administration (FDA) has approved AZOR(TM) (amlodipine and olmesartan medoxomil) for the treatment of hypertension, also known as high blood pressure. |
| 2007-05-22 | Daiichi Sankyo | Results Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007) First Release of Data for New Combination daiichisankyo.com ↗
Combining the calcium channel blocker amlodipine besylate with the angiotensin receptor blocker olmesartan medoxomil, produced significant mean reductions in seated systolic and diastolic blood pressure in patients with hypertension, according to data presented at the American Society of Hypertension¨s Twenty-Second Annual Scientific Meeting at Exposition (ASH 2007). |
| 2006-11-29 | Daiichi Sankyo | Regulatory DAIICHI SANKYO, INC. ANNOUNCES FILING OF NEW DRUG APPLICATION FOR AMLODIPINE BESYLATE / OLMESARTAN MEDOXOMIL COMBINATION FOR THE TREATMENT OF HYPERTENSION daiichisankyo.com ↗
Daiichi Sankyo, Inc. announced today that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for a fixed dose combination of two antihypertensives, the calcium channel blocker (CCB) amlodipine besylate (currently marketed by Pfizer as Norvasc®) and the angiotensin receptor blocker (ARB) olmesartan medoxomil, or BENICAR®. |
| 2005-10-07 | Daiichi Sankyo | Regulatory European Mutual Certification Completed for Antihypertensive daiichisankyo.com ↗
has successfully cleared the screening by relevant European member countries and is scheduled to obtain marketing authorization for the European market |
All press releases naming this drug 33 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 85 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olmesartanmedoxomil | “This study was designed to assess the antihypertensive benefit of the olmesartan medoxomil 40 mg/hydrochlorothiazide (HCTZ) 12.5 mg combination versus olmesartan medoxomil 40...” PMID 20593911 ↗ 201076“These formulations include olmesartan medoxomil/amlodipine, rosuvastatin, ezetimibe, and dapagliflozin, with indapamide included in selected formulations.” NCT07679828 ↗ “In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.” NCT04061824 ↗ “For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy.” NCT03015311 ↗ “Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.” NCT01838850 ↗ “ATB-U101 is a fixed-dose combination tablet containing Olmesartan medoxomil 40 mg and Dapagliflozin 10 mg.” NCT07590466 ↗ “Olmesartan medoxomil 40 mg, Amlodipine 10 mg and Hydrochlorothiazide 25 mg” NCT02962258 ↗ “Amlodipine orotate 10mg/Olmesartan medoxomil 40mg” NCT02058472 ↗ “Olmesartanmedoxomil (OM)40 mg tablets once daily” NCT00441350 ↗ “tablet, olmesartan medoxomil(CS-866) 40mg” NCT01493856 ↗ “Drug: Olmesartan medoxomil” NCT01180205 ↗ |
| Known as | ATB-1011 | “ATB-1011 (Olmetec, Olmesartan medoxomil 40 mg) and ATB-1012 (Forxiga, Dapagliflozin 10 mg) will be co-administered as a single oral dose under fasting conditions (minimum 10...” NCT07590466 ↗ |
| Known as | Benicar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07547878 ↗ |
| Known as | Benicar (olmesartan medoxomil) | “Benicar (olmesartan medoxomil)” NCT00151775 ↗ |
| Known as | CS-866 | “tablet, olmesartan medoxomil(CS-866) 40mg” NCT01493856 ↗ |
| Known as | OLM | “range of olmesartan medoxomil (OLM)/amlodipine (AML) doses” PMID 22909147 ↗ Oct 2012 |
| Known as | olmesartan | “We examined the effects of olmesartan, an ARB, on primary composite outcome of doubling of serum creatinine, endstage renal disease and death in type 2 diabetic patients with...” PMID 21993710 ↗ Oct 20113“Patients received olmesartan monotherapy for 12 weeks, followed by additional use of azelnidipine (n=103) or hydrochlorothiazide (n=104) for 24 weeks after randomization.” PMID 19667251 ↗ Aug 2009 “adding amlodipine 5 or 10 mg/day to olmesartan medoxomil (hereafter olmesartan) 20 mg/day in patients not adequately controlled on olmesartan monotherapy.” PMID 19499960 ↗ 2009 “we assigned 4447 patients with type 2 diabetes to receive olmesartan (at a dose of 40 mg once daily) or placebo for a median of 3.2 years.” PMID 21388309 ↗ Mar 2011 |
| Known as | Olmetec | “ATB-1011 (Olmetec, Olmesartan medoxomil 40 mg) and ATB-1012 (Forxiga, Dapagliflozin 10 mg) will be co-administered as a single oral dose under fasting conditions (minimum 10...” NCT07590466 ↗ |
| Action | Inhibit | “angiotensin II receptor blocker” NCT00134160 ↗ |
| Route | Oral | “All patients received a single oral dose of olmesartan medoxomil based on the individual's age and bodyweight.” PMID 22880942 ↗ Dec 2012 |